People who qualifies for LYNPARZA are people who have primary peritoneal cancer, fallopian tube cancer, Ovarian Cancer, Breast Cancer or Prostate Cancer.
To qualify for LYNPARZA you must have advanced cancer and be in complete or partial response to first line platinum based chemotherapy.
With breast cancer to qualify for LYNPARZA you must have metastatic or early breast cancer and have been previously treated with chemotherapy.
For prostate cancer to qualify for LYNPARZA you must have metastatic castration-resistant prostate cancer and be treated in combination with abiraterone and prednisone or prednisolone.
LYNPARZA can make you feel nauseous, tired or weak and cause vomiting, headache, loss of appetite, low red blood cell counts, diarrhea and blood in urine or poop.
Other side effects of LYNPARZA include fever, frequent infections, shortness of breath, stomach pain or heartburn, bruising or bleeding more easily, back, joint or muscle pain, nose or throat irritation, change in taste and irritation of the mouth or even mouth sores.
You do not lose hair on LYNPARZA like you may on chemotherapy drugs.
Lynparza is not a chemotherapy drug so it does not cause hair loss.
The risk of LYNPARZA are Thrombocytopenia, Leukopenia, High blood pressure, blood clots, lung problems such as pneumonitis, low blood cell counts and bone marrow problems such as acute Myeloid Leukemia or Myelodysplastic Syndrome.
Foods you should avoid when taking LYNPARZA are Seville oranges and grapefruit and also avoid drinking any Seville orange juice or grapefruit juice as it can interfere with how Lynparza works and can increase your risk of side effects.
The life expectancy of someone on LYNPARZA is between 30 months to 56.5 months although some people have lived 7 years when taking LYNPARZA.
The drug LYNPARZA extends life for up to 30 months to 56.5 months although some people have lived a bit longer and even up to 7 years when taking Lynparza. '
The life expectancy on Lynparza depends on the type of cancer and how far progressed the cancer is.
The survival rate for LYNPARZA is 67 percent as 67 percent of people taking LYNPARZA live at least 7 years and sometimes longer when taking Lynparza.
LYNPARZA does shrink tumors in certain types of cancers which include breast cancer tumors, ovarian cancer tumors and pancreatic cancer tumors.
Lynparza can shrink and slow the growth of ovarian cancer tumors as well as pancreatic tumors and can sometimes even achieve complete responses.
52 percent of people that take Lynparza for breast cancer see their tumors shrink.
Lynparza can be used to treat early stage or even metastatic breast cancer with a BRCA1 or BRCA2 mutation.
The success rate of LYNPARZA is around 92.8 percent depending on the cancer it is treating.
For most people the success rate of LYNPARZA is 92.8 percent although it can be as low as 61 percent to 70 percent for other cancers.
LYNPARZA is covered by Medicare and 100 percent of Medicare prescription drug plans cover Lynparza.
Most health insurance will also cover Lynparza but you may need to pay a small copay.
LYNPARZA is approved in the US and was approved by the FDA on May 31st 2023.
LYNPARZA is not considered a chemotherapy.
Lynparza is a non chemotherapy cancer medication that is a PARP inhibitor, that inhibits poly ADP ribose polymerase, which is an enzyme that is involved in repair of DNA.
The drug Lynparza is used to treat certain types of advanced cancer that has come back after previous treatment and for women that have been newly diagnosed with advanced cancer.
Lynparza is often used to treat primary peritoneal cancer, fallopian tube cancer, prostate cancer, pancreatic cancer, ovarian cancer and breast cancer.
The drug Lynparza can also be used to treat early breast cancer which has a high risk of coming back.
If your doctor determines that Lynparza is safe and effective for you, you'll likely take the drug Lynparza long term.
Lynparza treatment for ovarian cancer can last for up to 2 years or as long as the drug is safe and effective for you.
The success rate of Lynparza is 61 percent.
Lynparza is worth taking as research has found that the drug Lynparza decreased a persons' risk of recurrence of invasive breast cancer and increased the length of time of no signs or symptoms of cancer.
At three years, 85.9% of people who took Lynparza were alive without invasive breast cancer, compared with 77.1% of people in the placebo group.
When taking Lynparza you should avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
The cost for Lynparza 100 mg oral tablet is around $8,883.00 for a supply of 60 tablets, depending on the pharmacy you get it from.
100 percent of Medicare plans will cover the cost of Lynparza and most other health insurance plans will also cover the cost of Lynparza.
The risks and possible side effects of Lynparza are fatigue, asthenia, abdominal pain, vomiting and anemia.